BTIG Sees 260% Upside In Mustang Bio With PT of $11; Early-Stage MB-101 Starts Dosing Brain Tumor Patients

Mustang Bio Inc MBIO and the City of Hope, an independent cancer research and treatment center, have dosed the first patient in Phase 1 trial evaluating MB-101 in patients with leptomeningeal brain tumors.
The trial will enroll up to 30 patients and determine the safety and feasibility of administering MB-101 through the ICV Rickham catheter over four weekly cycles in patients with glioblastoma (Arm 1) and ependymoma or medulloblastoma (Arm 2).
The primary endpoints being evaluated are toxicity, and the survival at three months.
Secondary endpoints include overall survival, CAR T and endogenous T cell levels, cytokine levels and phenotype detection in peripheral blood, tumor cyst fluid, and cerebrospinal fluid.
Analyst Update: BTIG initiated coverage on Mustang Bio with Buy Rating, with a Price Target of $11 (upside of around 260%)
Price Action: MBIO shares are up 5.59% at $3.02 during the premarket session on the last check Tuesday.

Analyst Calendar